Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: TomOrt who wrote (28691)	4/13/1999 9:30:00 PM
From: Henry Niman	Respond to of 32384

It's good to see LGND getting some good press out of the AACR meetings. The data in rats is quite impressive and of course the human data will of interest to many. The combination with Tamoxifen is also of interest. Although Tamoxifen reduced the incidence of breast cancer, deaths due to side effects caused the overall mortality to be the same. Breast cancer prevention of course is a huge market and the prevention studies are being sponsored by NSABP. If Targretin comes anywhere close to the rat data, NASBP will be interested in combining Targretin with the winner of the Tamoxifen/Evista battle to see how well the combo does in reducing the incidence of breast cancer in high risk individuals.